Results 71 to 80 of about 177,775 (151)

Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity

Critical Care Medicine, 2019
Karthik, Suresh, Franco, D'Alessio
openaire   +3 more sources

Pregnancy Outcomes After in Utero Exposure to Immune Checkpoint Inhibitors. [PDF]

Curr Oncol
Bou Zerdan M, Kfoury B, Aoun E, Hmaidan SD, Wilke RN, How JA, Woodard TL, Soliman PT, McKenzie LJ.   +8 more
europepmc   +1 more source

Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review. [PDF]

Front Oncol
Ismail H, Hassan A.
europepmc   +1 more source

Rethinking Invasive Mediastinal Staging in the Era of Neoadjuvant Immune-Checkpoint Inhibitors. [PDF]

Thorac Cancer
Silva SB, Wada DT, Dessotte LU, Wada LS, Faccio AA, Cipriano FG.   +5 more
europepmc   +1 more source

Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies. [PDF]

ESMO Gastrointest Oncol
Alsina M, Beunza-Sola M, Fernández-Montes A, Padrón-Rodriguez B, de Castro EM, Valencia-Soto CM, Fleitas T, Arrazubi V, Lecumberri A, Cáseda I, Agirre B, Lainez N, Arasanz H, Rivera F, Vera R.   +14 more
europepmc   +1 more source

Immune-Related Polyradiculoneuropathy Associated With Immune Checkpoint Inhibitors: A Comprehensive Case Series. [PDF]

Brain Behav
Llauradó A, Lainez E, Ariño H, Gratacòs-Viñola M, Seoane JL, Roca-Herrera M, Restrepo-Vera JL, Sanchez-Tejerina D, Raguer N, Juntas-Morales R.   +9 more
europepmc   +1 more source

The application and challenges of immune checkpoint inhibitors in lung cancer therapy. [PDF]

Front Immunol
Li B, Ren Y, Zhang X.
europepmc   +1 more source

Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments. [PDF]

Front Oncol
Welch RL, Moziak K, Zang X, Martin AM.
europepmc   +1 more source

Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. [PDF]

Theranostics
Xia W, Zhang H, Liu L, Tu C, Song X.
europepmc   +1 more source

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences. [PDF]

Cancer Commun (Lond)
Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E, Lisberg A, Collineau B, Beaufils M, Gonçalves A, Tejeda M, Chrétien AS, Rochigneux P.   +18 more
europepmc   +1 more source